An international multi-site, randomized controlled trial of a mindfulness-based psychoeducation group programme for people with schizophrenia

W T Chien, D Bressington, A Yip, T Karatzias, W T Chien, D Bressington, A Yip, T Karatzias

Abstract

Background: We aimed to test a mindfulness-based psychoeducation group (MBPEG), v. a conventional psychoeducation group (CPEG) v. treatment as usual (TAU), in patients with schizophrenia-spectrum disorders over a 24-month follow-up.

Method: This single-blind, multi-site, pragmatic randomized controlled trial was conducted in six community treatment facilities across three countries (Hong Kong, mainland China and Taiwan). Patients were randomly allocated to one of the treatment conditions, and underwent 6 months of treatment. The primary outcomes were changes in duration of re-hospitalizations and mental state (Positive and Negative Syndrome Scale; PANSS) between baseline and 1 week, and 6, 12 and 18 months post-treatment.

Results: A total of 300 patients in each country were assessed for eligibility between October 2013 and 30 April 2014, 38 patients per country (n = 342) were assigned to each treatment group and included in the intention-to-treat analysis. There was a significant difference in the length of re-hospitalizations between the three groups over 24 months (F 2,330 = 5.23, p = 0.005), with MBPEG participants having a shorter mean duration of re-hospitalizations than those in the other groups. The MBPEG and CPEG participants had significant differential changes in proportional odds ratios of complete remission (all individual PANSS items <3) over the 24-month follow-up (37 and 26%, respectively), as opposed to only 7.2% of the TAU group (χ2 = 8.9 and 8.0, p = 0.001 and 0.003, relative risk = 3.5 and 3.1, 95% confidence interval 2.0-7.2 and 1.6-6.3).

Conclusions: Compared with TAU and CPEG, MBPEG improves remission and hospitalization rates of people with schizophrenia spectrum disorders over 24 months.

Keywords: Mindfulness-based interventions; psychoeducation; randomized controlled trials; re-hospitalization; schizophrenia spectrum disorders.

Figures

Fig. 1.
Fig. 1.
Consolidated Standards of Reporting Trials (CONSORT) diagram of clinical trial for two treatment and usual-care groups. OPC, Out-patient clinic; PANSS, Positive and Negative Syndrome Scale; SLOF, Specific Level of Functioning Scale; SSQ6, six-item Social Support Questionnaire; ITAQ, Insight and Treatment Attitudes Questionnaire; ITT, intention-to-treat.

References

    1. Andreasen N, Carpenter W, Kane J, Lasser R, Marder S, Weinberger D (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry 62, 441–449.
    1. Bäuml J, Froböse T, Kraemer S, Rentrop M, Pitschel-Walz G (2006). Psychoeducation: a basic psychotherapeutic intervention for patients with schizophrenia and their families. Schizophrenia Bulletin 32 (Suppl. 1), S1–S9.
    1. Bell M, Milstein R, Beam-Goulet J, Lysaker P, Cicchetti D (1992). The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale: reliability, comparability, and predictive validity. Journal of Nervous and Mental Disease 180, 723–728.
    1. Bellg AJ, Borrelli B, Resnick B, Hecht J, Minicucci DS, Ory M, Ogedegbe G, Orwig D, Ernst D, Czajkowski S; Treatment Fidelity Workgroup of the NIH Behavior Change Consortium (2004). Enhancing treatment fidelity in health behaviour change studies: best practices and recommendations from the NIH Behavior Change Consortium. Health Psychology 23, 443–451.
    1. Bhagyavathi HD, Mehta UM, Thirthalli J, Kumar CN, Kumar JK, Subbakrishna DK, Gangadhar BN (2015). Cascading and combined effects of cognitive deficits and residual symptoms on functional outcome in schizophrenia – a path-analytical approach. Psychiatry Research 229, 264–271.
    1. Chadwick P, Hughes S, Russell D, Russell I, Dagnan D (2009). Mindfulness groups for distressing voices and paranoia: a replication and randomized feasibility trial. Behavioural and Cognitive Psychotherapy 27, 403–412.
    1. Chan SW, Yip B, Tso S, Cheng BS, Tam W (2009). Evaluation of a psychoeducation program for Chinese patients with schizophrenia and their family caregivers. Patient Education and Counselling 75, 67–76.
    1. Chien WT, Bressington D (2015). A randomized controlled trial of a nurse-led structured psychosocial intervention program for people with first-onset mental illness in psychiatric outpatient clinics. Psychiatry Research 229, 277–286.
    1. Chien WT, Chan WCS, Thompson DR (2006). Effects of a mutual support group for families of Chinese people with schizophrenia: 18-month follow-up. British Journal of Psychiatry 189, 41–49.
    1. Chien WT, Lee YMI (2013). The mindfulness-based psychoeducation program for Chinese patients with schizophrenia. Psychiatric Services 64, 376–379.
    1. Chien WT, Thompson DR (2014). Effects of a mindfulness-based psycho-education programme for Chinese patients with schizophrenia: two-year follow-up. British Journal of Psychiatry 205, 52–59.
    1. Chlesa A, Serretti A (2011). Mindfulness-based cognitive therapy for psychiatric disorders: a systematic review and meta-analysis. Psychiatry Research 187, 441–453.
    1. Coldman EL, Addington J, Addington D (2002). Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica 106, 286–290.
    1. First MB, Spitzer RL, Gibbon M, Williams JBW (2001). User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders – Research Version. Biometrics Research, New York State Psychiatric Institute: New York.
    1. Freeman D, Garety PA, Kuipers E, Fowler D, Bebbington PE (2002). A cognitive model of persecutory delusions. British Journal of Clinical Psychology 41, 331–347.
    1. Global Burden of Disease Study 2013 Collaborators (2015). Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386, 743–800.
    1. Guo X, Zhai J, Liu Z, Fang M, Wang B, Wang C, Hu B, Sun X, Lv L, Lu Z, Ma C (2010). Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: a randomized, 1-year study. Archives of General Psychiatry 67, 895–904.
    1. Hargus E, Crane C, Barnhofer T, William JM (2010). Effects of mindfulness on meta-awareness and specificity of describing prodromal symptoms in suicidal symptoms. Emotion 10, 34–42.
    1. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261–276.
    1. Khoury B, Lecomte T, Gaudiano BA, Paguin K (2013). Mindfulness interventions for psychosis: a meta-analysis. Schizophrenia Research 150, 176–184.
    1. Kingston T, Dooley B, Bates A, Lawlor E, Malone K (2007). Mindfulness-based cognitive therapy for residual depressive symptoms. Psychology and Psychotherapy 80, 193–203.
    1. Lam AHY, Chien WT (2016). The effectiveness of mindfulness-based intervention for people with schizophrenia: a systematic review. Neuropsychiatry (London) 6, 208–222.
    1. Langer IÁ, Cangas AJ, Salcedo E, Fuentes B (2012). Applying mindfulness therapy in a group of psychotic individuals: a controlled study. Behavioural and Cognitive Psychotherapy 40, 105–109.
    1. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J; American Psychiatric Association; Steering Committee on Practice Guidelines (2004). Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 161 (Suppl. 2), 1–56.
    1. Ma SH, Teasdale JD (2004). Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects. Journal of Consulting and Clinical Psychology 72, 31–40.
    1. Macpherson R, Jerrom B, Hughes A (1996). A controlled study of education about drug treatment in schizophrenia. British Journal of Psychiatry 168, 709–717.
    1. McEvoy JP, Apperson LJ, Appelbaum PS, Ortilip P, Brecosky J, Hammill K, Geller JL, Roth L (1989). Insight in schizophrenia: its relationship to acute psychopathology. Journal of Nervous and Mental Disease 177, 43–47.
    1. National Institute for Health and Care Excellence (NICE) (2014). Psychosis and Schizophrenia in Adults: Prevention and Management. NICE guideline CG178 (March 2014). NICE: London, UK.
    1. Pull CB (2009). Current empirical status of acceptance and commitment therapy. Current Opinion in Psychiatry 22, 55–60.
    1. Schennach R, Riedel M, Obermeier M, Spellmann I, Musil R, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ (2015). What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. European Archives of Psychiatry and Clinical Neuroscience 265, 107–116.
    1. Schneider LC, Struening EL (1983). SLOF: a behavioral rating scale for assessing the mentally ill. Social Work Research and Abstracts 19, 9–21.
    1. Williams JM, Teasdale JD, Segal ZV (2000). Mindfulness-based cognitive therapy reduces over-general autobiographical memory in formerly depressed patients. Journal of Abnormal Psychology 109, 150–155.
    1. Xia J, Merinder LB, Belqamwar MR (2011). Psychoeducation for schizophrenia. The Cochrane Database of Systematic Reviews, issue 6, CD002831.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다